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Abstract
Background. 4-Aminopyridine (4-AP) is a drug that is used to improve motor
fatigue in patients suffering from multiple sclerosis (MS). Medication error can
occur, as commercial preparation may not be available in some countries. Case
Presentation. A 58-year-old woman with progressive MS presented with status
epilepticus. She was receiving 4-AP for more than 3 years. The symptoms started
soon after the ingestion of a single pill that was supposed to contain 10 mg 4-AP,
but further investigations revealed that each pill had been inadvertently prepared
with an 100 mg 4-AP concentration. The patient was admitted to the intensive
care unit (ICU) for appropriate management (orotracheal intubation, sedation,
and antiepileptic drugs). The first electroencephalogram (EEG) showed abundant
irregular spike-waves on the left central regions. Neurological condition gradually
improved from day 7, while the EEG did not reveal any more electrical seizures
but was still consistent with toxic encep...
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Background. 4-Aminopyridine (4-AP) is a drug that is used to improve motor fatigue in patients suffering from multiple sclerosis
(MS). Medication error can occur, as commercial preparationmay not be available in some countries.Case Presentation. A 58-year-
old woman with progressive MS presented with status epilepticus. She was receiving 4-AP for more than 3 years. The symptoms
started soon after the ingestion of a single pill that was supposed to contain 10mg 4-AP, but further investigations revealed that each
pill had been inadvertently prepared with an 100mg 4-AP concentration.The patient was admitted to the intensive care unit (ICU)
for appropriate management (orotracheal intubation, sedation, and antiepileptic drugs). The first electroencephalogram (EEG)
showed abundant irregular spike-waves on the left central regions. Neurological condition gradually improved from day 7, while
the EEG did not reveal any more electrical seizures but was still consistent with toxic encephalopathy.The patient stayed in the ICU
until day 13. At discharge from the rehabilitation ward (2.5 months later), the patient had not yet recovered her previous cognitive
and functional condition. Conclusion. A single 100mg 4-AP accidental overdose may cause serious immediate complications, with
a slow and incomplete neurological recovery.
1. Introduction
4-Aminopyridine (4-AP) is indicated for the improvement
of walking speed and motor fatigue in multiple sclerosis
(MS). An overdose in 4-AP can produce detrimental side
effects. In the majority of cases, overdose is accidental and
related to an error in the compounding of the drug [1, 2].
Due to the fact that no commercial preparation for 4-AP is
available in Belgium, the medication must be compounded
by the pharmacist upon medical prescription. We report a
case of sustained encephalopathy following status epilepticus
induced by 4-AP overdose.
2. Case Presentation
A 58-year-old woman with a medical history of secondary
progressive MS was admitted to the emergency department
(ED) for convulsive status epilepticus. Before admission,
the Kurtzke Expanded Disability Status Score (EDSS) was
6.5/10. The patient was treated by 4-AP (10mg orally, bid)
for more than 3 years, without previous adverse effects.
In addition, she was also receiving baclofen (10mg bid),
levothyroxine 50𝜇g/d, citalopram 20mg/d, and interferon-
beta1b (3 subcutaneous injections per week).
A few minutes after the ingestion of a single pill of 4-
AP, she started to complain from severe abdominal pain. The
pill came from a new box of a pharmacy preparation that
was supposed to contain 10mg of 4-aminopyridine per pill.
Less than one hour after the ingestion, she developed rigidity,
ocular revulsion, alteration of consciousness, and finally gen-
eralized tonic-clonic seizures. The first medical rescue team
administered intravenous diazepam before hospital admis-
sion. On arrival in the ED, the patient had a Glasgow Coma
Scale (GCS) score of 9 (E1V4M4). After recurrence of gen-
eralized tonic-clonic seizures, she received 2mg lorazepam
and 2mgmidalozam as intravenous bolus and a loading dose
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of 1200mg valproic acid intravenously. Orotracheal intuba-
tion was required for mechanical ventilation. Sedation was
obtained by continuous infusion of midazolam (5mg/h) and
propofol (100mg/h). In the intensive care unit (ICU), after the
regression of the effects of the neuromuscular blocking agent
used for intubation, no hypertonia was observed. However,
facial myoclonus rapidly reappeared. Antiepileptic therapy
included a continuous intravenous infusion of valproic acid
(1mg/kg/h) together with levetiracetam (750mg orally, bid).
This resulted in the complete disappearance of anymyoclonic
or epileptic activity. Routine laboratory investigations were
not relevant. Toxicological screening performed after ICU
admission failed to reveal the presence of other substances
than the patient’s usual medications; there was no evidence
for baclofen overdose. Brain magnetic resonance imaging
(MRI) was similar to that obtained a few months before
and confirmed the stability of the lesions related to MS.
Double inversion recovery sequence imaging demonstrated
the presence of intracortical demyelinating lesions in the
insula and left parietal cortex. The patient was monitored
in the ICU by continuous electroencephalographic (EEG)
recording. The first EEG recording, performed upon admis-
sion to the ICU 12 hours after initial symptoms, showed
generalized slowing at 6-7 cycles per second with abundant
irregular spike- and polyspike-waves on the left frontocentral
regions (Figure 1(a)). The epileptiform waves diffused at
times to the right frontocentral regions and occasionally
became rhythmic during 10 second bursts. On day 3, EEG
monitoring showed a discontinuous pattern with bursts of
electrical activity characterized by left frontocentral slow
spikes at 1-2Hz on a diffusely slowed background. As the
sedation was reduced, EEG became gradually continuous
with diffusely slow background activity at 6-7 cycles per
second but still showed bursts of delta waves intermixed with
slow spikes on the left frontocentral regions (Figure 1(b)).
Sedative drugs (midazolam 6mg/h and propofol 200mg/
h) were maintained for 5 days for prevention of recurrent
seizures. From day 1 to day 6, the GCS never exceeded 7
(E2V1M4). Starting from day 7, the patient was able to open
the eyes spontaneously, but there was no interaction with the
environment and no response to verbal command. On day 8,
the patient was able to move spontaneously the four limbs.
On day 11, she had a clear motor response (M6) to verbal
command. Extubation was possible on day 12. She presented
a painful dysphonia due to right vocal cord paresis. She
had difficulties in understanding complex commands and
remained confused. The patient developed left basal pneu-
monia as a late complication in the ICU. She was transferred
to the neurology department on day 13. In addition to the
altered cognitive state, the patient’s neurological examination
showed marked left predominant spastic paraparesis. Walk-
ing was impossible. The patient presented urinary retention
anddysphagia. Cognitive testing revealedmemory, executive,
language, attentional, and visual-spatial difficulties.TheEDSS
was 8.5/10. EEG performed on day 22 showed a restored
reactive structured background rhythm at 8.5–9.5 cycles per
second, with predominant delta waves on the left frontal
region, rarely intermixed with isolated slow spikes. On day
34, she was admitted to the rehabilitation ward, still confused
and bedridden. She benefited from intensive physiotherapy,
speech therapy, bladder training, and cognitive rehabilitation
during 2.5 months. At discharge, she was able to walk a few
meters with bilateral aid but needed partial aid with transfers.
She could also swallow liquids and solid food. Her cognitive
status and bladder function were partially improved. Her
EDSS was 7/10.
The box containing the remaining pills was brought by
the family to the hospital for toxicological analysis. A pill
was analyzed by high performance liquid chromatography
(HPLC) coupled to ultraviolet (UV) detection and was com-
pared to a standard pill of 10mg of 4-AP prepared by the
hospital pharmacy. The 4-AP content of the pill that was
ingested by the patient was at least 8 times greater (>80mg)
than the standard.The pharmacist admitted that each pill was
erroneously prepared with a concentration of 100mg.
3. Discussion
The exact pathophysiology of 4-AP toxicity remains to be
elucidated. 4-AP is a potassium channel-blocking drug. The
prolongation of the action potential may facilitate calcium
entry into the cell; the increased influx of calcium is thought
to enhance neurotransmission by releasing acetylcholine.
Accidental 4-AP overdose may result in serious neurological
events ranging from dystonia to altered consciousness and
seizures [3, 4]. In a case series published by Burton et al. about
three patients (46 to 54 years of age)whohad ingested the first
dose of a 4-AP preparation containing erroneously between
90.1mg and 125.6mg of 4-AP, unusual sensory and behavioral
symptoms progressed within minutes to hours to status
epilepticus [1]. In one patient only, the EEG revealed focal
spike and wave activity.The patients required aggressive ICU
treatment with intubation, benzodiazepines, and phenytoin.
They were discharged with significant residual neurologic
disability. However, seizures have to be clearly separated
from other abnormal movements. In a recent review of
the literature following their own case presentation, King
et al. analyzed 19 cases of 4-AP toxicity and found that 5
patients presented isolated seizure and 6 status epilepticus.
Intubation was performed not only in these 11 patients
but also in 3 patients who did not experience seizures [3].
Benzodiazepines were administered to the majority of the
patients as well as anticonvulsants (phenytoin or valproic
acid) in reaction to seizures. However, some patients may
present with dystonic choreoathetoidmovements and altered
consciousness [5–7]. The motor symptoms are most likely
caused not by epileptogenic activity in the brain but by
neuromuscular junction hyperactivity. Dysfunction of the
basal ganglia, due to an altered acetylcholine release induced
by 4-aminopyridine, could explain the abnormal involuntary,
choreathetoidmovements in the patients.This conditionmay
be partly responsive to benzodiazepines but is not associated
with epileptic changes on the EEG. The interpretation of the
EEG may therefore be careful, with a distinction between
nonconvulsive status epilepticus and toxic encephalopathy
with specific electroencephalographic changes. The risk for
the patient, if the interpretation of the EEGdata is not correct,
is that excessive pharmacological treatment could result in
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Figure 1: EEG recordings performed upon admission of the patient to the ICU (a) and at day 8 (b). (a) EEG traces show continuous
epileptiform spikes and spike-waves at 2Hz on the left frontocentral regions on a generalized slowed background intermixed with
medicamentous beta waves. (b) EEG shows irregular short bursts of slow spikes and delta waves on the left frontocentrotemporal regions.
Background activity at day 8 still shows diffuse beta waves, of medicamentous origin.
prolonged sedation, mechanical ventilation, and ICU stay.
Our patient presented initial status epilepticus confirmed
by initial EEG findings. From day 3 onwards, no further
electrical seizures were recorded. EEG was consistent with a
prolonged toxic encephalopathy, as also observed in other sit-
uations of drug overdose. For example, inMS patients treated
by baclofen, overdosemay also result in altered consciousness
with epileptic-like EEG changes which do not require specific
antiepileptic therapy [8]. In other case reports, 4-AP overdose
has been shown to cause prolonged toxic encephalopathy
without initial seizures.This cannot be explained by the kinet-
ics of oral 4-AP.The determination of 4-AP blood concentra-
tion is not routinely available in most laboratories. It would
be helpful in confirming exposure, but not for the assessment
of acute neurotoxicity as there is an important overlap of 4-
AP concentrations causing seizure or not.The drug is rapidly
absorbed and ismainly excreted in the urine in an unchanged
form (90.3%), with the role of hepatic metabolism being
minimal. The serum terminal half-life of the molecule is
between 5–6.5 hours and 24 hours. In contrast, the duration
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of toxic encephalopathy may be several days or even weeks.
The neurologic recovery is not complete in all of the patients
reported in the literature, as well as in our case [3]. Some
patients suffered from a greater and chronic neurologic dis-
ability after the overdose episode; short or long-termmemory
loss is also a possible delayed complication [9]. The clinical
course is not influenced by any specific treatment.
In conclusion, for the intensive care physicians, it is
important to be aware of the clinical and electrophysiological
specificities relating to 4-AP overdose, in order to avoid
unnecessary treatments for nonconvulsive status epilepticus,
togetherwith prolonged sedation,mechanical ventilation and
ICU stay.
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